This is noteworthy as other studies have linked the expression of PD-L1 on CD8+ and CD4+ T cells with patient response to ICB, suggesting PD-L1 expression in CD8+ T cells as a prognostic marker in melanoma.9,52 As the innate immune response is activated by radiotherapy10 and ADAR recently described as an important factor in resistance to RT,4 we decided to perform a second round of functional experiments consisting of irradiating our cancer cells and evaluating viability and clonogenicity after RT. The gene discussed is ADAR; the disease is melanoma.